PlainPharmaWatch
CMS PY 2024 Company profile Open Payments data

TAKEDA PHARMACEUTICALS U.S.A., INC.

TAKEDA PHARMACEUTICALS U.S.A., INC. reported $158.2M in payments to physicians and teaching hospitals across 185,019 transactions in CMS Open Payments PY 2024.

Pharmaceutical payment transparency data for TAKEDA PHARMACEUTICALS U.S.A., INC.. Ranked #16 of 1,797 companies by total payments. Source: CMS Open Payments, Program Year 2024.

Payment Overview

Total Payments

$158.2M

1.2% of all payments

Transactions

185,019

$855.28 avg

Recipients

171,595

$922.19 avg

Industry Rank

#16

of 1,797 companies

What the Data Shows for TAKEDA PHARMACEUTICALS U.S.A., INC.

In Program Year 2024, TAKEDA PHARMACEUTICALS U.S.A., INC. reported $158,243,899.02 in payments to 171,595 physicians and teaching hospitals across 185,019 individual transactions — an average of $855.28 per transaction and $922.19 per recipient. That total places TAKEDA PHARMACEUTICALS U.S.A., INC. at rank #16 out of 1,797 companies in the CMS Open Payments database, representing 1.2% of all industry payments reported nationwide for the year. Payment volume at this scale is characteristic of manufacturers with broad prescriber engagement, active clinical research programs, or patented therapies generating ongoing royalty obligations.

The payment mix for TAKEDA PHARMACEUTICALS U.S.A., INC. spans 9 distinct categories defined by CMS — including general payments (consulting, speaker fees, meals, travel), research payments tied to clinical trials, and ownership or investment interests. The largest single category is "Royalty or License" at $44.5M, accounting for 28.1% of the company's reported total and 27 transactions. This distribution matters because different payment types carry different regulatory and ethical implications: research funding supports clinical development, while general payments like meals and speaker fees have been studied for their correlation with prescribing patterns in peer-reviewed journals such as JAMA Internal Medicine.

Recipient concentration is another useful lens. The top 5 recipients of payments from TAKEDA PHARMACEUTICALS U.S.A., INC. received $0.00 combined — 0.0% of the company's total — with the remaining 100.0% distributed across the rest of the 171,595 recipients. A relatively distributed top-5 share suggests broader engagement across the prescriber community rather than concentration among a handful of high-value relationships. All figures above are drawn directly from the CMS Open Payments Public Use Files for PY2024 and are disclosed under the Physician Payments Sunshine Act; this page summarizes reported financial transfers and does not represent medical advice or judgment about individual prescribing decisions.

Payment Breakdown by Type

TAKEDA PHARMACEUTICALS U.S.A., INC. made 9 types of payments. "Royalty or License" accounts for 28.1%.

Royalty or License $44.5M

28.1% · 27 transactions

Consulting Fee $10.4M

6.6% · 4,062 transactions

Compensation for Services Other Than Consulting $6.3M

4.0% · 984 transactions

Food and Beverage $3.5M

2.2% · 162,008 transactions

Space Rental or Facility Fees $3.2M

2.0% · 454 transactions

Grant $1.8M

1.1% · 24 transactions

Travel and Lodging $1.1M

0.7% · 2,745 transactions

Education $538.0K

0.3% · 1,287 transactions

Payment Type Amount Transactions
Royalty or License $44.5M 27
Consulting Fee $10.4M 4,062
Compensation for Services Other Than Consulting $6.3M 984
Food and Beverage $3.5M 162,008
Space Rental or Facility Fees $3.2M 454
Grant $1.8M 24
Travel and Lodging $1.1M 2,745
Education $538.0K 1,287
Charitable Contribution $276.5K 4

Payment Size Analysis

Average transaction size: $855.28. Average per recipient: $922.19.

Total Amount

$158,243,899.02

Avg per Transaction

$855.28

Avg per Recipient

$922.19

Payment Transparency Context

The Physician Payments Sunshine Act (part of the Affordable Care Act) requires pharmaceutical and medical device manufacturers to report payments and transfers of value to physicians and teaching hospitals. These payments can include consulting fees, research grants, speaker fees, food and beverages, travel, royalties, and other forms of compensation.

Industry Total (2024)

$13.3B

across 1,797 companies

TAKEDA PHARMACEUTICALS U.S.A., INC. Share

1.2%

#16 by total payments

Frequently Asked Questions

How much did TAKEDA PHARMACEUTICALS U.S.A., INC. pay to physicians and hospitals in 2024?
TAKEDA PHARMACEUTICALS U.S.A., INC. made $158,243,899.02 in payments to physicians and hospitals in Program Year 2024, across 185,019 individual transactions. This represents 1.2% of all industry payments reported to CMS Open Payments.
How many physicians received payments from TAKEDA PHARMACEUTICALS U.S.A., INC.?
TAKEDA PHARMACEUTICALS U.S.A., INC. made payments to 171,595 physicians and teaching hospitals in 2024. The average payment per recipient was $922.19.
What types of payments did TAKEDA PHARMACEUTICALS U.S.A., INC. make?
TAKEDA PHARMACEUTICALS U.S.A., INC. made 9 different types of payments. The largest category was "Royalty or License" at $44.5M, representing 28.1% of all payments.
How does TAKEDA PHARMACEUTICALS U.S.A., INC. rank among pharmaceutical companies?
TAKEDA PHARMACEUTICALS U.S.A., INC. ranks #16 out of 1,797 companies by total payment amount in the CMS Open Payments database for 2024.
What is the average payment size from TAKEDA PHARMACEUTICALS U.S.A., INC.?
The average transaction from TAKEDA PHARMACEUTICALS U.S.A., INC. was $855.28 in 2024. The company made 185,019 total transactions to 171,595 recipients.
Are the top recipients concentrated for TAKEDA PHARMACEUTICALS U.S.A., INC.?
The top 5 recipients received $0.00 from TAKEDA PHARMACEUTICALS U.S.A., INC., representing 0.0% of the company's total payments. Payments are relatively well-distributed across recipients.
Where does the payment data for TAKEDA PHARMACEUTICALS U.S.A., INC. come from?
This data comes from the CMS Open Payments program (Sunshine Act), which requires pharmaceutical and medical device companies to report payments and transfers of value to physicians and teaching hospitals. The data covers Program Year 2024.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.3B across 1,797 companies.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainPharmaWatch Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.